Ovarian Mucinous Tumor
NCI Definition: A benign, borderline, or malignant epithelial tumor of the ovary characterized by the presence of neoplastic epithelial cells that contain intracytoplasmic mucin and may resemble the epithelial cells of the endocervix or gastrointestinal tract. 
Ovarian mucinous tumors most frequently harbor alterations in KRAS, TP53, CDKN2A, CDKN2B, and PIK3CA .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in ovarian mucinous tumor .
There is 1 clinical trial for ovarian mucinous tumor, of which 0 are open and 1 is completed or closed. Of the trial that contains ovarian mucinous tumor as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
Nivolumab and oregovomab are the most common interventions in ovarian mucinous tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.